Radiotherapy after D2 Lymph Node Dissection +/- Omentectomy in Gastric Cancer

Main Article Content

Yasemin Benderli Cihan
Baki Taştan


The review aims to address the indications and areas of radiotherapy in gastric cancer. Gastric cancer is the 5th most common cancer worldwide and ranks third in cancer deaths. It is an insidious disease and it is usually asymptomatic until it reaches the advanced stage. Surgical treatment is still standard treatment, although chemotherapy, radiotherapy and immunotherapy have been advancing in recent years. The lymph nodes of the stomach are collected in 16 groups and are classified from N1 to N3 according to their stations. Parallel to this order of lymph nodes, lymph node dissections are separated from D0 to D3. D0 dissection N1 group lymph nodes were not dissected; D1 dissection dissolves the entire N1; D2 dissection N1 and N2 group lymph nodes all dissected; D3 dissection indicates that all of the lymph nodes of N1, N2, N3. It is concluded that gastric cancer has a poor prognosis and aggressive cancer. The standard treatment is surgery. In the surgical treatment, total / subtotal gastrectomy + D1 (+/-) D2 lymph node dissection +/- omentectomy is performed. D2 dissected +/- omentectomy gastric cancer postoperative radiotherapy, the role of RT in the treatment, the target volume of RT, new RT techniques to reduce the potential toxicity and which group of patients is not clear is clear. The results of a prospective randomized study will provide more reliable results.

Radiotherapy, lymph node dissection, gastric cancer, omentectomy.

Article Details

How to Cite
Cihan, Y. B., & Taştan, B. (2019). Radiotherapy after D2 Lymph Node Dissection +/- Omentectomy in Gastric Cancer. Asian Journal of Research in Medicine and Medical Science, 1(1), 14-17. Retrieved from
Mini Review Article